Lupin Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin announced positive Phase 1a trial results for LNP8701, a novel oral SOS1 inhibitor for metastatic solid tumors, presented at the ASCO 2026 Annual Meeting. The drug demonstrated good safety and tolerability across all tested dose levels with favorable pharmacokinetics. Early efficacy showed 2 patients completing 12 cycles (1 year) and 1 patient completing 14 cycles with stable disease. Lupin plans to continue into Phase 1b trials in India exploring both monotherapy and combination treatment approaches for solid tumors.
Positive pipeline development signal, but the drug remains in early-stage development with years of trials ahead before potential commercialization. No immediate commercial or revenue impact.